IN2015DN00910A - - Google Patents

Info

Publication number: IN2015DN00910A
Authority: IN; India
Prior art keywords: methyl; indol; phenyl; eythl; laminomethyl
Prior art date: 2006-06-12

Application number

Other languages

English (en)

Inventor

Murat Acemoglu

Joginder S Bajwa

David John Parker

Joel Slade

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-12

Filing date

2007-06-07

Publication date

2015-07-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015DN00910(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-06-07 Application filed by Novartis Ag filed Critical Novartis Ag

2015-07-10 Publication of IN2015DN00910A publication Critical patent/IN2015DN00910A/en

Links

CPVSLHQIPGTMLH-UHFFFAOYSA-N 2-(2-methyl-1h-indol-3-yl)ethanamine Chemical compound C1=CC=C2C(CCN)=C(C)NC2=C1 CPVSLHQIPGTMLH-UHFFFAOYSA-N 0.000 abstract 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 abstract 1
239000007858 starting material Substances 0.000 abstract 1
238000010189 synthetic method Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Indole Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IN910DEN2015 2006-06-12 2007-06-07 IN2015DN00910A (it)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US80452706P	2006-06-12	2006-06-12
US86787806P	2006-11-30	2006-11-30
PCT/US2007/070564 WO2007146718A2 (en)	2006-06-12	2007-06-07	Process for making n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino] methyl]phenyl]-2e-2-propenamide and starting materials therefor

Publications (1)

Publication Number	Publication Date
IN2015DN00910A true IN2015DN00910A (it)	2015-07-10

Family

ID=38832681

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN910DEN2015 IN2015DN00910A (it)	2006-06-12	2007-06-07

Country Status (31)

Country	Link
US (2)	US20090306405A1 (it)
EP (2)	EP2032533B8 (it)
JP (2)	JP5431926B2 (it)
KR (2)	KR101493530B1 (it)
CN (4)	CN102167678B (it)
AR (1)	AR061296A1 (it)
AU (1)	AU2007257883B2 (it)
BR (1)	BRPI0712847A2 (it)
CA (1)	CA2653657C (it)
CL (2)	CL2007001691A1 (it)
DK (1)	DK2032533T3 (it)
EC (1)	ECSP088978A (it)
ES (2)	ES2553255T3 (it)
GT (1)	GT200800282A (it)
HR (1)	HRP20130798T1 (it)
IL (2)	IL195211A (it)
IN (1)	IN2015DN00910A (it)
JO (1)	JO2900B1 (it)
MA (1)	MA30513B1 (it)
MX (2)	MX2008015898A (it)
MY (1)	MY147576A (it)
NO (1)	NO341870B1 (it)
NZ (1)	NZ572707A (it)
PE (2)	PE20120221A1 (it)
PL (1)	PL2032533T3 (it)
PT (1)	PT2032533E (it)
RU (1)	RU2448090C2 (it)
TN (1)	TNSN08507A1 (it)
TW (1)	TWI395734B (it)
WO (1)	WO2007146718A2 (it)
ZA (1)	ZA200809490B (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT202000004075A1 (it)	2020-02-27	2021-08-27	Flamma Spa	Processo per la preparazione di panobinostat

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB146260A (en)	1918-07-11	1921-08-11	Elektro Osmose Ag	A process for preparing proteids charged with immune substances
GB8531612D0 (en) *	1985-12-23	1986-02-05	Beecham Wuelfing Gmbh & Co Kg	Compounds
PE20020354A1 (es) *	2000-09-01	2002-06-12	Novartis Ag	Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AU2002237261A1 (en)	2001-01-09	2002-07-24	Novartis Pharma Gmbh	Rapid method for screening compounds for in vivo activity
NZ544689A (en)	2001-11-06	2007-08-31	Novartis Ag	Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
AU2007257882B2 (en) *	2006-06-12	2011-09-08	Secura Bio Inc.	Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide

2007
- 2007-06-07 IN IN910DEN2015 patent/IN2015DN00910A/en unknown
- 2007-06-07 WO PCT/US2007/070564 patent/WO2007146718A2/en not_active Ceased
- 2007-06-07 CN CN2011100629486A patent/CN102167678B/zh active Active
- 2007-06-07 US US12/302,572 patent/US20090306405A1/en not_active Abandoned
- 2007-06-07 MX MX2008015898A patent/MX2008015898A/es active IP Right Grant
- 2007-06-07 CA CA2653657A patent/CA2653657C/en active Active
- 2007-06-07 CN CN2012103501544A patent/CN103086944A/zh active Pending
- 2007-06-07 MX MX2012002221A patent/MX366213B/es unknown
- 2007-06-07 KR KR20087030232A patent/KR101493530B1/ko not_active Expired - Fee Related
- 2007-06-07 KR KR1020147026120A patent/KR101540194B1/ko not_active Expired - Fee Related
- 2007-06-07 BR BRPI0712847-9A patent/BRPI0712847A2/pt not_active IP Right Cessation
- 2007-06-07 PL PL07784350T patent/PL2032533T3/pl unknown
- 2007-06-07 AU AU2007257883A patent/AU2007257883B2/en not_active Ceased
- 2007-06-07 CN CN2011100630820A patent/CN102174008A/zh active Pending
- 2007-06-07 EP EP07784350.6A patent/EP2032533B8/en active Active
- 2007-06-07 NZ NZ572707A patent/NZ572707A/en not_active IP Right Cessation
- 2007-06-07 ES ES11179043.2T patent/ES2553255T3/es active Active
- 2007-06-07 ES ES07784350T patent/ES2416286T3/es active Active
- 2007-06-07 PT PT77843506T patent/PT2032533E/pt unknown
- 2007-06-07 DK DK07784350.6T patent/DK2032533T3/da active
- 2007-06-07 RU RU2008151726/04A patent/RU2448090C2/ru active
- 2007-06-07 JP JP2009515575A patent/JP5431926B2/ja active Active
- 2007-06-07 EP EP11179043.2A patent/EP2394991B1/en active Active
- 2007-06-07 CN CNA2007800217257A patent/CN101466674A/zh active Pending
- 2007-06-07 HR HRP20130798TT patent/HRP20130798T1/hr unknown
- 2007-06-08 PE PE2011002097A patent/PE20120221A1/es active IP Right Grant
- 2007-06-08 AR ARP070102498A patent/AR061296A1/es unknown
- 2007-06-08 PE PE2007000720A patent/PE20080851A1/es active IP Right Grant
- 2007-06-11 TW TW096120985A patent/TWI395734B/zh not_active IP Right Cessation
- 2007-06-11 CL CL200701691A patent/CL2007001691A1/es unknown
- 2007-06-12 JO JO2007219A patent/JO2900B1/en active
2008
- 2008-11-06 ZA ZA200809490A patent/ZA200809490B/xx unknown
- 2008-11-10 IL IL195211A patent/IL195211A/en active IP Right Grant
- 2008-11-28 MY MYPI20084865A patent/MY147576A/en unknown
- 2008-12-05 TN TNP2008000507A patent/TNSN08507A1/en unknown
- 2008-12-10 GT GT200800282A patent/GT200800282A/es unknown
- 2008-12-12 EC EC2008008978A patent/ECSP088978A/es unknown
- 2008-12-12 MA MA31472A patent/MA30513B1/fr unknown
2009
- 2009-01-09 NO NO20090137A patent/NO341870B1/no not_active IP Right Cessation
2010
- 2010-09-13 CL CL2010000973A patent/CL2010000973A1/es unknown
2011
- 2011-09-23 US US13/243,001 patent/US8536346B2/en active Active
2013
- 2013-10-25 JP JP2013222442A patent/JP5809223B2/ja active Active
2014
- 2014-07-28 IL IL233836A patent/IL233836A/en active IP Right Grant

Also Published As

Publication number	Publication date
CN103086944A (zh)	2013-05-08
EP2394991A1 (en)	2011-12-14
PL2032533T3 (pl)	2013-08-30
JP5809223B2 (ja)	2015-11-10
KR20140117703A (ko)	2014-10-07
JP5431926B2 (ja)	2014-03-05
HK1126759A1 (en)	2009-09-11
NO341870B1 (no)	2018-02-12
IL233836A0 (en)	2014-09-30
AU2007257883A1 (en)	2007-12-21
PE20120221A1 (es)	2012-03-21
NZ572707A (en)	2011-12-22
CN102167678B (zh)	2013-08-28
US8536346B2 (en)	2013-09-17
CL2010000973A1 (es)	2011-07-01
CN102174008A (zh)	2011-09-07
WO2007146718A2 (en)	2007-12-21
CN102167678A (zh)	2011-08-31
KR101540194B1 (ko)	2015-07-28
BRPI0712847A2 (pt)	2012-08-07
ES2553255T3 (es)	2015-12-07
TW200815345A (en)	2008-04-01
RU2008151726A (ru)	2010-07-20
KR101493530B1 (ko)	2015-02-13
MX2008015898A (es)	2009-01-12
HK1162029A1 (en)	2012-08-17
DK2032533T3 (da)	2013-07-01
WO2007146718A3 (en)	2008-06-19
ZA200809490B (en)	2009-10-28
HRP20130798T1 (en)	2013-09-30
RU2448090C2 (ru)	2012-04-20
JO2900B1 (en)	2015-09-15
EP2032533B1 (en)	2013-04-03
GT200800282A (es)	2009-03-09
ECSP088978A (es)	2009-01-30
PE20080851A1 (es)	2008-08-18
NO20090137L (no)	2009-03-03
ES2416286T3 (es)	2013-07-31
AR061296A1 (es)	2008-08-20
KR20090015969A (ko)	2009-02-12
US20090306405A1 (en)	2009-12-10
CN101466674A (zh)	2009-06-24
TNSN08507A1 (en)	2010-04-14
PT2032533E (pt)	2013-06-28
EP2394991B1 (en)	2015-09-23
US20120010418A1 (en)	2012-01-12
CA2653657A1 (en)	2007-12-21
MY147576A (en)	2012-12-31
JP2014058532A (ja)	2014-04-03
TWI395734B (zh)	2013-05-11
MX366213B (es)	2019-07-01
IL195211A (en)	2014-08-31
EP2032533B8 (en)	2013-12-11
IL195211A0 (en)	2009-08-03
CL2007001691A1 (es)	2008-05-16
MA30513B1 (fr)	2009-06-01
IL233836A (en)	2017-05-29
EP2032533A2 (en)	2009-03-11
JP2009540008A (ja)	2009-11-19
AU2007257883B2 (en)	2011-09-29
CA2653657C (en)	2015-10-27

Publication	Publication Date	Title
TNSN08501A1 (en)	2010-04-14	Salts of n-hydroxy-3-[4-[[[2-(2- methyl-ih-indol-3-yl) ethyl ]amino]methyl ]phenyl ]-2e-2-propenamide
MY149337A (en)	2013-08-30	Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
JO3099B1 (ar)	2017-03-15	طريقة تصنيع املاح من n- هيدروكسي -3- [4-[[[2-(2-مثيل-h 1-اندول -3-يل)ايثيل]امينو]مثيل]فنيل]-e-2-2بروبان اميد
ZA200809383B (en)	2009-11-25	Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl] amino]methyl]phenyl]-2E-2propenamide
WO2007146718A3 (en)	2008-06-19	Process for making n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino] methyl]phenyl]-2e-2-propenamide and starting materials therefor
UA97243C2 (en)	2012-01-25	Crystalline anhydrous form of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
HK1132509A (en)	2010-02-26	Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
DOP2008000069A (es)	2009-03-31	Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]]fenil]-2e-2-propenamida.
CY1117493T1 (el)	2017-04-26	Αλατα του ν-υδροξυ-3-[4-[[[2-(2-μεθυλ-1η-ινδολ-3-υλ)αιθυλ]αμινο]μεθυλο]φαινυλο]-2ε-2-προπεναμιδιου